UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...
Shares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
Gene therapy company uniQure N.V. (QURE) announced Tuesday that the company reached agreement with the U.S. Food and Drug ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
The U.S. FDA has greenlit the first steps of Uniqure NV’s accelerated approval pathway for gene therapy AMT-130 to treat Huntington’s disease. The agency said data from the ongoing phase I/II studies ...
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a potential treatment for ...
The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...